key: cord-0714758-66xcvveg
authors: FitzGerald, Richard; Dickinson, Laura; Else, Laura; Fletcher, Thomas; Hale, Colin; Amara, Alieu; Walker, Lauren; Penchala, Sujan Dilly; Lyon, Rebecca; Shaw, Victoria; Greenhalf, William; Bullock, Katie; Lavelle-Langham, Lara; Reynolds, Helen; Painter, Wendy; Holman, Wayne; Ewings, Sean; Griffiths, Gareth; Khoo, Saye
title: Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection
date: 2022-03-10
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac199
sha: b1711251fd9fbad6b1c4468cf329cc1b393b2856
doc_id: 714758
cord_uid: 66xcvveg

ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled in AGILE CST-2 (NCT04746183). Saliva, nasal and tear concentrations were 3, 21 and 22% that of plasma. Saliva and nasal NHC concentrations were significantly correlated with plasma (p<0.0001).

An extended therapeutic goal of antiviral therapy is the prevention of infection in individuals that have been exposed to an infected person. SARS-CoV-2 infection occurs through inhalation or inoculation of virus onto upper respiratory airways and mucosal surfaces and in order to be an effective prophylactic agent, drug must penetrate into these sites in sufficient quantities.

Molnupiravir (EIDD-2801; MK-4482), a prodrug of the ribonucleoside analogue 14 β-d-N4hydroxycytidine (NHC), has recently been licensed in the UK and received FDA Emergency Use Authorisation (EUA) in the US for the treatment of symptomatic COVID-19 in adults with at least one risk factor for developing severe disease. Following oral administration, molnupiravir is rapidly hydrolysed by esterases to NHC, which is phosphorylated by host kinases to active intracellular metabolite EIDD-1931-5'-triphosphate (EIDD-2061) [1] . AGILE, a UK platform for early-phase trials of novel COVID-19 therapies [2] , has evaluated molnupiravir within its AGILE Candidate-Specific Trial (CST)-2 seamless phase Ib/IIa protocol. We previously reported phase Ib evaluation of molnupiravir across three dosing arms (300, 600 and 800 mg twice daily), establishing that 800 mg twice daily for 5 days was suitable for progression to phase II [3] , which is currently recruiting.

We report here the pharmacokinetics of molnupiravir and NHC in saliva, nasal secretions and tears, in comparison with plasma concentrations within AGILE CST-2 Ib. M a n u s c r i p t 4

Molnupiravir pharmacokinetics were evaluated as part of a phase I dose-escalation study (300, 600, 800 mg twice daily) in patients with PCR-confirmed SARS-CoV-2 infection, within 5 days of symptom onset and presenting with mild or moderate disease (NCT04746183). The study design has previously been described [3] and further details can be found in the Supplementary Material.

Plasma and non-plasma (saliva, nasal secretions and tears) samples were collected at predose, 0.5, 1, 2, and 4 hours post-dose on study days 1 and 5. Plasma samples were collected as previously described [4] . Non-plasma sample collections and molnupiravir dosing conditions are described in the Supplementary Material.

Molnupiravir and NHC concentrations were determined at the University of Liverpool Bioanalytical Facility (Liverpool, UK). Plasma and saliva concentrations were quantified using a validated LC-MS method [4] . NHC in nasal secretions and tears (swabs) were determined using an adaptation of this method described in the Supplementary Material. All assays were validated in accordance with FDA [5] and EMA guidelines [6] .

Given the small sample size, representation of the pharmacokinetic data was largely exploratory and descriptive. Samples below the lower limit of quantification (LLQ; <2.5 ng/mL) at pre-dose on day 1 were included as 0 ng/mL; those <LLQ beyond pre-dose on day 1 were included as LLQ/2 (1.25 ng/mL). NHC area under the concentration-time curve 0-4 hours (AUC 0-4 ), maximum concentration (C max ) and time to maximum concentration (T max ) A c c e p t e d M a n u s c r i p t 5 were determined using non-compartmental analysis (Phoenix 64, WinNonlin, v. 8.3, Certara, Princeton, NJ, USA). NHC intercompartmental non-plasma:plasma ratios (R NP:P ) were calculated on day 1 and 5 for each individual using the plasma as reference (non-plasma AUC 0-4 /plasma AUC 0-4 ). Patients without a full profile between 0-4 hours were excluded from AUC 0-4 summary statistics, and those with sample(s) missing between 0-2 hours were excluded from C max and T max summary statistics.

Linear mixed effects models were applied to evaluate the relationship between logtransformed NHC concentrations in plasma and non-plasma compartments on day 1 and 5 (IBM SPSS Statistics v. 25.0, IBM Corporation, Armonk, NY, USA). Concentrations below assay LLQ were excluded.

Of the twelve participants (n=4 per dosing arm), 9/12 (75%) were female, median (range) baseline age, weight and BMI were 50 years (22-80), 79 kg (54-134) and 29 kg/m 2 (21-51); time from symptom onset to randomisation and start of treatment was 5 days (3-5).

Ten of the twelve individuals (83%) completed the full treatment schedule. One patient in the 300 mg cohort took 1 of 2 tablets for the second and third dose and a participant in the 800 mg cohort withdrew after the second dose. All pharmacokinetic data were included. We observed saliva NHC concentrations that were 3% that of plasma, whereas exposure in nasal secretions and tears was higher at approximately 20% that of plasma (based on pooled AUC 0-4 ratios). Of the measured saliva, nasal and tear samples, 6, 50 and 61%, respectively were within or above the NHC EC 90 against SARS-CoV-2 in primary human airway epithelia 

The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ss-d-N4-hydroxycytidine in human plasma and saliva

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

17) mL) 1731 (44) * 1071 (38) * 1137 (96) * 749 (50) # # n=2, § n=1 AUC 0-4 : area under the concentration-time curve over 0 hours (pre-dose) to 4 hours post-dose; C max : maximum concentration; T max : time of maximum concentration

The authors wish to thank the patients that participated in the AGILE CST-2 molnupiravir trial and all the staff involved at the NIHR Royal Liverpool and Broadgreen Clinical Research Facility and the team at Liverpool Bioanalytical Facility, who were involved in the

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 13 8. Sheahan